SM
ATXI

Sabby Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Sabby Management’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-63,060
Closed -$157K – 53
2024
Q3 		$157K Buy
63,060
+25,666
+69% +$73.6K 0.08% 19
2024
Q2 		$131K Buy
37,394
+28,448
+318% +$165K 0.09% 24
2024
Q1 		$99K Buy
+8,946
New +$106K 0.06% 33
2023
Q3 		– Sell
-7,378
Closed -$647K – 108
2023
Q2 		$647K Buy
7,378
+3,646
+98% +$300K 0.53% 17
2023
Q1 		$326K Buy
3,732
+212
+6% +$19.6K 0.28% 37
2022
Q4 		$306K Buy
+3,520
New +$638K 0.27% 36

Other funds holding ATXI

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Sabby Management's ATXI Position: Q4 2024 in Review

Sabby Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2024, closing a stake of 63,060 shares — an estimated $157K sold.

Sabby Management first reported a position in ATXI in Q4 2022 and held it in 6 quarters. The position peaked at $647K in Q2 2023. 7 funds tracked by Wall St. Rank hold ATXI as of Q4 2024.

  • Sabby Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Sabby Management sold 63,060 Avenue Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $157K.
  • Sabby Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2022 and held it in 6 quarters.
  • Sabby Management's Avenue Therapeutics, Inc. Common Stock position peaked at $647K in Q2 2023.
  • 7 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Sabby Management's 13F filing for Q4 2024, filed 14 Feb 2025.